Anzeige
Mehr »
Login
Mittwoch, 13.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EWCS | ISIN: LU2598331598 | Ticker-Symbol: TW10
Tradegate
13.11.24
08:01 Uhr
17,245 Euro
+0,020
+0,12 %
1-Jahres-Chart
TENARIS SA Chart 1 Jahr
5-Tage-Chart
TENARIS SA 5-Tage-Chart
RealtimeGeldBriefZeit
17,36017,38510:48
17,36017,38510:48
GlobeNewswire (Europe)
348 Leser
Artikel bewerten:
(2)

Tenaris SA: Tenaris Announces 2024 Third Quarter Results

Finanznachrichten News

The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Free Cash Flow, Net cash / debt and Operating working capital days. See exhibit I for more details on these alternative performance measures.

LUXEMBOURG, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) ("Tenaris") today announced its results for the quarter ended September 30, 2024 in comparison with its results for the quarter ended September 30, 2023.

Summary of 2024 Third Quarter Results
(Comparison with second quarter of 2024 and third quarter of 2023)

3Q 20242Q 20243Q 2023
Net sales ($ million)2,9153,322(12%)3,238(10%)
Operating income ($ million)5375125%868(38%)
Net income ($ million)45934832%547(16%)
Shareholders' net income ($ million)44833534%537(17%)
Earnings per ADS ($)0.810.5937%0.91(11%)
Earnings per share ($)0.400.2937%0.46(11%)
EBITDA* ($ million)6886506%1,004(31%)
EBITDA margin (% of net sales)23.6%19.6% 31.0%

*EBITDA in 2Q 2024 includes a $171 million loss from the provision for ongoing litigation related to the acquisition of a participation in Usiminas. If this charge was not included EBITDA would have amounted to $821 million, or 24.7% of sales.

Net sales in the third quarter were affected by lower prices in the Americas and lower demand in the USA, Mexico and Saudi Arabia as well as lower line pipe shipments in Argentina. Margins were relatively resilient with our EBITDA margin falling 1.1% quarter on quarter on a comparable basis while net income recovered after the extraordinary provisions recorded by Tenaris and its associate company Ternium in the last quarter.

During the quarter, our free cash flow amounted to $373 million and, after spending $182 million on share buybacks, our positive net cash position amounted to $4.0 billion at September 30, 2024.

Interim Dividend Payment

Our board of directors approved the payment of an interim dividend of $0.27 per share ($0.54 per ADS), or approximately $300 million, according to the following timetable:

  • Payment date: November 20, 2024
  • Record date: November 19, 2024
  • Ex-dividend for securities listed in Europe: November 18, 2024
  • Ex-dividend for securities listed in the United States and Mexico: November 19, 2024

Follow-on Share Buyback Program

Tenaris's Board of Directors approved a $700 million follow-on share buyback program under the authority granted by the annual general meeting of shareholders held on June 2, 2020.

Under the previous $1.2 billion share buyback, which ran from November 5, 2023 to August 2, 2024, the Company purchased a total number of ordinary shares representing 6.07% of its total issued share capital measured as at the launch of the program. This follow-on share buyback program will cover up to $700 million (excluding customary transaction fees), subject to a maximum of 46,373,915 ordinary shares representing the remainder 3.93% of the Company's issued share capital (measured also as at the launch of the original program) that may be repurchased under the above-referred authority (which authorizes repurchases up to a maximum of 10% of the share capital).

The decision and opportunity of launching this follow-on buyback program is driven by the Company's significant cash flow generation and strong balance sheet.

The follow-on buyback program is expected to be launched in the near future and finish by March 26, 2025. It will be executed by a primary financial institution on the Milan Stock Exchange, with the intention to cancel the ordinary shares acquired through the program.

The buybacks may be ceased, paused and continued at any time, subject to compliance with applicable laws and regulations.

Tenaris will provide updates on the buyback program via press releases and on the Investors section of its corporate website. The buybacks will be carried out subject to market conditions and in compliance with applicable laws and regulations, including the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052.

Market Background and Outlook

Oil prices appear relatively stable and support industry investment despite uncertainty about Asian demand growth and geopolitical tensions.

The decline in OCTG prices in North America that we have seen over the past two years has now come to an end as drilling activity has stabilized and the level of US OCTG imports has come down.

The new government in Mexico is implementing its energy policy, drilling activity in the near term is subdued, while next year we expect that it will recover. In Argentina, the economic environment is improving, which should support investment in pipeline infrastructure and drilling activity in the Vaca Muerta shale.

In the Middle East, while gas drilling activity remains at a stable level, we see some reduction in oil activity and rationalization of inventories, including pipes, to protect cash flow.

In the fourth quarter, our sales and EBITDA will be lower than the third quarter, affected by lower sales in Mexico and Saudi Arabia and the delayed impact of OCTG pricing in the Americas. Overall, our 2024 second half results will be in line with our investor day guidance in September. Going into 2025, we expect our sales and EBITDA to recover with an increase in shipments in North America and the Middle East and a rebound in OCTG prices in North America.

Analysis of 2024 Third Quarter Results

Tubes

The following table indicates, for our Tubes business segment, sales volumes of seamless and welded pipes for the periods indicated below:

Tubes Sales volume (thousand metric tons)3Q 20242Q 20243Q 2023
Seamless746805(7%)7440%
Welded191228(16%)16913%
Total9371,033(9%)9133%

The following table indicates, for our Tubes business segment, net sales by geographic region, operating income and operating income as a percentage of net sales for the periods indicated below. During this quarter, the coating service results attributable to the coating business acquired from Mattr, which were previously included in our Others segment, have been reclassified to our Tubes segment and comparative amounts have been reclassified accordingly.

Tubes3Q 20242Q 20243Q 2023
(Net sales - $ million)
North America1,2731,439(12%)1,700(25%)
South America484599(19%)608(20%)
Europe2802694%23121%
Asia Pacific, Middle East and Africa754823(8%)55636%
Total net sales ($ million)2,7903,130(11%)3,095(10%)
Coating services to third parties included in Tubes ($ million)70675%19273%
Operating income ($ million)52745915%841(37%)
Operating margin (% of sales)18.9%14.7% 27.2%

Net sales of tubular products and services decreased 11% sequentially and 10% year on year. Sequentially, volumes decreased 9% and average selling prices excluding the coating services on third parties pipes decreased 2%. In North America sales declined due to lower prices throughout the region and lower activity in the United States and Mexico. In South America we had lower pipeline sales in Argentina and lower conductor sales in Brazil partially compensated by a start of shipments to the Raia offshore line pipe project. In Europe sales increased thanks to the continued shipments to the Sakarya offshore line pipe project and higher sales of OCTG in Romania and Turkey which more than compensated for lower sales in the North Sea. In Asia Pacific, Middle East and Africa further sales in Saudi Arabia under inventory replenishment program, stable sales to the United Arab Emirates and a high level of shipments to Iraq, attenuated a drop in sales in sub-Saharan Africa, China and the rest of the Middle East.

Operating results from tubular products and services amounted to a gain of $527 million in the third quarter of 2024 compared to a gain of $459 million in the previous quarter and a gain of $841 million in the third quarter of 2023. In the second quarter of 2024 our Tubes operating income included a $171 million loss from the provision for ongoing litigation related to the acquisition of a participation in Usiminas and a $14 million gain from a positive legal claim resolution in Mexico. Excluding these two effects Tubes operating income in the second quarter of 2024 would have amounted to $616 million and the current quarter would have been 14% lower following the decline in prices and sales.

Others

The following table indicates, for our Others business segment, net sales, operating income and operating income as a percentage of net sales for the periods indicated below:

Others3Q 20242Q 20243Q 2023
Net sales ($ million)125192(35%)143(13%)
Operating income ($ million)1052(81%)27(64%)
Operating margin (% of sales)7.9%27.3% 19.0%

Net sales of other products and services decreased 35% sequentially and decreased 13% year on year. Sequentially, sales declined mainly due to lower sales of coiled tubing, sucker rods and oil services in Argentina.

Selling, general and administrative expenses, or SG&A, amounted to $454 million, or 15.6% of net sales, in the third quarter of 2024, compared to $497 million, 15.0% in the previous quarter and $433 million, 13.4% in the third quarter of 2023. Sequentially, the decline in SG&A is mainly due to lower shipment costs due to a reduction in volumes shipped and a decrease in services and fees, taxes and others.

Other operating results amounted to a gain of $11 million in the third quarter of 2024, compared to a loss of $170 million in the previous quarter and a $36 million gain in the third quarter of 2023. In the second quarter of 2024 we recorded a $171 million loss from provision for ongoing litigation related to the acquisition of a participation in Usiminas.

Financial results amounted to a gain of $48 million in the third quarter of 2024, compared to a gain of $57 million in the previous quarter and a gain of $67 million in the third quarter of 2023. Financial result of the quarter is mainly attributable to a $50 million net finance income from the net return of our portfolio investments offset by other financial results.

Equity in earnings (losses) of non-consolidated companies generated a gain of $8 million in the third quarter of 2024, compared to a loss of $83 million in the previous quarter and a loss of $110 million in the third quarter of 2023. These results are mainly derived from our participation in Ternium (NYSE:TX). The previous quarter included an $83 million loss from the provision for ongoing litigation related to the acquisition of a participation in Usiminas on our investment in Ternium.

Income tax charge amounted to $134 million in the third quarter of 2024, compared to $138 million in the previous quarter and $278 million in the third quarter of 2023. With a similar income before equity earnings of non-consolidated companies and income tax, the tax charge of the quarter was sequentially lower mainly due to a lower impact of the foreign exchange devaluation in Mexico on the fiscal values of fixed assets and inventory.

Cash Flow and Liquidity of 2024 Third Quarter

Net cash generated by operating activities during the third quarter of 2024 was $552 million, compared to $935 million in the previous quarter and $1.3 billion in the third quarter of 2023. During the third quarter of 2024 cash generated by operating activities includes a net working capital reduction of $48 million.

With capital expenditures of $179 million, our free cash flow amounted to $373 million during the quarter. After share buybacks of $182 million in the quarter, our net cash position amounted to $4.0 billion at September 30, 2024.

Analysis of 2024 First Nine Months Results

9M 20249M 2023Increase/(Decrease)
Net sales ($ million)9,67911,454(15%)
Operating income ($ million)1,8603,497(47%)
Net income ($ million)1,5582,812(45%)
Shareholders' net income ($ million)1,5202,789(45%)
Earnings per ADS ($)2.674.72(43%)
Earnings per share ($)1.342.36(43%)
EBITDA* ($ million)2,3263,890(40%)
EBITDA margin (% of net sales)24.0%34.0%

*EBITDA in 9M 2024 includes a $174 million loss from the provision for ongoing litigation related to the acquisition of a participation in Usiminas. If this charge was not included EBITDA would have amounted to $2,499 million, or 25.8% of sales.

Our sales in the first nine months of 2024 decreased 15% compared to the first nine months of 2023 as volumes of tubular products shipped decreased 4%, tubes average selling prices decreased 15% excluding the coating services on third parties pipes, while sales in the Others segment remained flat. Following the decrease in sales, mainly due to the tubes average price decline, EBITDA margin declined from 34% to 24% and EBITDA declined 40%. EBITDA in the first nine months of 2024 includes a $174 million loss from the provision for ongoing litigation related to the acquisition of a participation in Usiminas, included in other operating expenses. Additionally, related to the same case, net income includes an $86 million loss from our participation in Ternium.

Cash flow provided by operating activities amounted to $2.4 billion during the first nine months of 2024, including a a reduction in working capital of $324 million. After capital expenditures of $512 million, our free cash flow amounted to $1.9 billion. Following a dividend payment of $459 million in May 2024 and share buybacks for $985 million in the nine months, our positive net cash position amounted to $4.0 billion at the end of September 2024.

The following table shows our net sales by business segment for the periods indicated below:

Net sales ($ million)9M 20249M 2023Increase/(Decrease)
Tubes9,21295%10,98796%(16%)
Others4675%4674%(0%)
Total9,679 11,454 (15%)

Tubes

The following table indicates, for our Tubes business segment, sales volumes of seamless and welded pipes for the periods indicated below:

Tubes Sales volume (thousand metric tons)9M 20249M 2023Increase/(Decrease)
Seamless2,3282,428(4%)
Welded687707(3%)
Total3,0163,136(4%)

The following table indicates, for our Tubes business segment, net sales by geographic region, operating income and operating income as a percentage of net sales for the periods indicated below:

Tubes9M 20249M 2023Increase/(Decrease)
(Net sales - $ million)
North America4,3016,071(29%)
South America1,6992,476(31%)
Europe8027546%
Asia Pacific, Middle East and Africa2,4101,68743%
Total net sales ($ million)9,21210,987(16%)
Coating services to third parties included in Tubes ($ million)30055441%
Operating income ($ million)1,7723,403(48%)
Operating margin (% of sales)19.2%31.0%

Net sales of tubular products and services decreased 16% to $9,212 million in the first nine months of 2024, compared to $10,987 million in the first nine months of 2023 due to a 4% decrease in volumes and a 15% decrease in average selling prices excluding the coating services on third parties pipes. Price declines were concentrated in the Americas, more so in North America, and were partially offset by increases in Europe and Asia Pacific, Middle East and Africa.

Operating results from tubular products and services amounted to a gain of $1,772 million in the first nine months of 2024 compared to a gain of $3,403 million in the first nine months of 2023. The decline in operating results is mainly due to the decline in average selling prices and the corresponding impact on margins. Additionally, in the first nine months of 2024 our Tubes operating income includes a charge of $174 million loss from the provision for ongoing litigation related to the acquisition of a participation in Usiminas, included in other operating expenses. On the other hand, operating income in the first nine months of 2024 includes gains amounting to $39 million from positive legal claims resolutions in Mexico and Brazil.

Others

The following table indicates, for our Others business segment, net sales, operating income and operating income as a percentage of net sales for the periods indicated below:

Others9M 20249M 2023Increase/(Decrease)
Net sales ($ million)4674670%
Operating income ($ million)8894(6%)
Operating margin (% of sales)18.9%20.1%

Net sales of other products and services which amounted to $467 million in the first nine months of 2024 remained flat in comparison to the the first nine months of 2023 as an increase in sales of oilfield services in Argentina and coiled tubing offset a decline in sales of sucker rods, excess raw materials and energy.

Operating results from other products and services amounted to a gain of $88 million in the first nine months of 2024, compared to a gain of $94 million in the first nine months of 2023. Results were mainly derived from our sucker rods business, coiled tubing and our oilfield services business in Argentina.

Selling, general and administrative expenses, or SG&A, amounted to $1,459 million in the first nine months of 2024, representing 15.1% of sales, and $1,449 million in the first nine months of 2023, representing 12.6% of sales. SG&A expenses increased as a percentage of sales due to the 15% decline in revenues, mainly due to lower Tubes average selling prices, and an increase of fixed costs partially offset by a reduction in selling expenses.

Other operating results amounted to a loss of $146 million in the first nine months of 2024, compared to a gain of $41 million in the same period of 2023. In the first nine months of 2024 we recorded a $174 million loss from provision for ongoing litigation related to the acquisition of a participation in Usiminas. In the first nine months of 2023 other operating income includes a non-recurring gain of $33 million corresponding to the transfer of the awards related to the Company's Venezuelan nationalized assets.

Financial results amounted to a gain of $81 million in the first nine months of 2024, compared to a gain of $128 million in the first nine months of 2023. While net finance income increased due to a higher net financial position, other financial results were negatively affected by a cumulative result of the U.S. dollar denominated Argentine bond previously recognized in other comprehensive income, while foreign exchange results decreased in the first nine months of 2024 in respect to the same period of 2023.

Equity in (losses) earnings of non-consolidated companies generated a loss of $27 million in the first nine months of 2024, compared to a gain of $39 million in the first nine months of 2023. These results were mainly derived from our equity investment in Ternium (NYSE:TX) and in the first nine months of 2024 were negatively affected by an $86 million loss from the provision for ongoing litigation related to the acquisition of a participation in Usiminas on our Ternium investment.

Income tax amounted to a charge of $357 million in the first nine months of 2024, compared to $852 million in the first nine months of 2023. The lower income tax charge reflects mainly the reduction in results at several subsidiaries.

Cash Flow and Liquidity of 2024 First Nine Months

Net cash provided by operating activities during the first nine months of 2024 amounted to $2.4 billion (including a reduction in working capital of $324 million), compared to cash provided by operations of $3.6 billion (net of a reduction in working capital of $248 million) in the first nine months of 2023.

Capital expenditures amounted to $512 million in the first nine months of 2024, compared to $453 million in the first nine months of 2023. Free cash flow amounted to $1.9 billion in the first nine months of 2024, compared to $3.1 billion in the first nine months of 2023.

Following a dividend payment of $459 million in May 2024 and share buybacks of $985 million in the nine months, our positive net cash position amounted to $4.0 billion at the end of September 2024.

Conference call

Tenaris will hold a conference call to discuss the above reported results, on November 7, 2024, at 08:00 a.m. (Eastern Time). Following a brief summary, the conference call will be opened to questions.

To listen to the conference please join through one of the following options:
ir.tenaris.com/events-and-presentationsor
https://edge.media-server.com/mmc/p/z7cmogvw/

If you wish to participate in the Q&A session please register at the following link:
https://register.vevent.com/register/BIf7b93fbc38f245839de51051af91f592

Please connect 10 minutes before the scheduled start time.

A replay of the conference call will also be available on our webpage at: ir.tenaris.com/events-and-presentations

Some of the statements contained in this press release are "forward-looking statements". Forward-looking statements are based on management's current views and assumptions and involve known and unknown risks that could cause actual results, performance or events to differ materially from those expressed or implied by those statements. These risks include but are not limited to risks arising from uncertainties as to future oil and gas prices and their impact on investment programs by oil and gas companies.

Consolidated Condensed Interim Income Statement

(all amounts in thousands of U.S. dollars)Three-month period ended
September 30,
Nine-month period ended
September 30,
2024202320242023
UnauditedUnaudited
Net sales2,915,4873,237,8369,678,70811,453,930
Cost of sales(1,935,560)(1,973,381)(6,213,226)(6,548,324)
Gross profit979,9271,264,4553,465,4824,905,606
Selling, general and administrative expenses(454,020)(432,682)(1,458,840)(1,448,765)
Other operating income16,68239,21942,16751,575
Other operating expenses(5,490)(3,091)(188,337)(10,971)
Operating income537,099867,9011,860,4723,497,445
Finance Income65,81556,100190,988149,853
Finance Cost(15,979)(19,179)(52,284)(87,103)
Other financial results, net(1,381)30,565(57,828)65,116
Income before equity in earnings of non-consolidated companies and income tax585,554935,3871,941,3483,625,311
Equity in earnings (losses) of non-consolidated companies7,605(110,382)(26,735)38,545
Income before income tax593,159825,0051,914,6133,663,856
Income tax(133,968)(278,200)(356,971)(851,804)
Income for the period459,191546,8051,557,6422,812,052
Attributable to:
Shareholders' equity448,066537,3111,520,2322,788,967
Non-controlling interests11,1259,49437,41023,085
459,191546,8051,557,6422,812,052


Consolidated Condensed Interim Statement of Financial Position

(all amounts in thousands of U.S. dollars)At September 30, 2024 At December 31, 2023
Unaudited
ASSETS
Non-current assets
Property, plant and equipment, net6,150,671 6,078,179
Intangible assets, net1,355,801 1,377,110
Right-of-use assets, net149,808 132,138
Investments in non-consolidated companies1,550,676 1,608,804
Other investments1,020,808 405,631
Deferred tax assets790,907 789,615
Receivables, net199,45911,218,130 185,95910,577,436
Current assets
Inventories, net3,762,705 3,921,097
Receivables and prepayments, net249,754 228,819
Current tax assets307,459 256,401
Trade receivables, net2,079,600 2,480,889
Derivative financial instruments8,727 9,801
Other investments2,798,807 1,969,631
Cash and cash equivalents715,0289,922,080 1,637,82110,504,459
Total assets 21,140,210 21,081,895
EQUITY
Shareholders' equity 17,200,408 16,842,972
Non-controlling interests 219,167 187,465
Total equity 17,419,575 17,030,437
LIABILITIES
Non-current liabilities
Borrowings14,405 48,304
Lease liabilities103,121 96,598
Derivative financial instruments- 255
Deferred tax liabilities479,187 631,605
Other liabilities318,498 271,268
Provisions87,3631,002,574 101,4531,149,483
Current liabilities
Borrowings485,996 535,133
Lease liabilities48,616 37,835
Derivative financial instruments3,230 10,895
Current tax liabilities291,032 488,277
Other liabilities380,577 422,645
Provisions221,870 35,959
Customer advances324,382 263,664
Trade payables962,3582,718,061 1,107,5672,901,975
Total liabilities 3,720,635 4,051,458
Total equity and liabilities 21,140,210 21,081,895


Consolidated Condensed Interim Statement of Cash Flows

(all amounts in thousands of U.S. dollars)Three-month period
ended September 30,
Nine-month period
ended September 30,
2024 2023 2024 2023
Unaudited Unaudited
Cash flows from operating activities
Income for the period 459,191 546,805 1,557,642 2,812,052
Adjustments for:
Depreciation and amortization 151,122 136,129 465,073 392,163
Bargain purchase gain - (3,162) (2,211) (3,162)
Provision for the ongoing litigation related to the acquisition of participation in Usiminas6,736 - 177,346 -
Income tax accruals less payments (108,788) 76,994 (222,350) 134,168
Equity in (losses) earnings of non-consolidated companies(7,605) 110,382 26,735 (38,545)
Interest accruals less payments, net(5,678) (22,986) (8,313) (44,926)
Changes in provisions (615) (17,998) (5,347) 21,935
Changes in working capital 48,003 414,887 323,521 248,125
Others, including net foreign exchange9,446 55,883 61,894 37,528
Net cash provided by operating activities551,812 1,296,934 2,373,990 3,559,338
Cash flows from investing activities
Capital expenditures (178,671) (170,376) (512,086) (452,625)
Changes in advances to suppliers of property, plant and equipment(4,968) (1,342) (15,483) 902
Acquisition of subsidiaries, net of cash acquired5,500 (100,311) 31,446 (104,419)
Additions to associated companies- (22,661) - (22,661)
Loan to joint ventures (1,392) (1,427) (4,137) (2,662)
Proceeds from disposal of property, plant and equipment and intangible assets13,182 648 19,317 9,023
Dividends received from non-consolidated companies- - 53,136 43,513
Changes in investments in securities(243,133) (809,796) (1,279,885) (2,597,425)
Net cash used in investing activities(409,482) (1,105,265) (1,707,692) (3,126,354)
Cash flows from financing activities
Dividends paid - - (458,556) (401,383)
Dividends paid to non-controlling interest in subsidiaries(5,862) (1,530) (5,862) (18,967)
Changes in non-controlling interests- 2,033 1,115 3,772
Acquisition of treasury shares (181,741) - (985,127) -
Payments of lease liabilities (17,944) (12,199) (51,326) (35,968)
Proceeds from borrowings 331,348 326,185 1,526,444 1,358,223
Repayments of borrowings (444,172) (381,886) (1,616,771) (1,524,973)
Net cash used in financing activities(318,371) (67,397) (1,590,083) (619,296)
(Decrease) increase in cash and cash equivalents(176,041) 124,272 (923,785) (186,312)
Movement in cash and cash equivalents
At the beginning of the period 848,695 755,271 1,616,597 1,091,433
Effect of exchange rate changes 8,652 (15,531) (11,506) (41,109)
(Decrease) increase in cash and cash equivalents(176,041) 124,272 (923,785) (186,312)
681,306 864,012 681,306 864,012


Exhibit I - Alternative performance measures

Alternative performance measures should be considered in addition to, not as substitute for or superior to, other measures of financial performance prepared in accordance with IFRS.

EBITDA, Earnings before interest, tax, depreciation and amortization.

EBITDA provides an analysis of the operating results excluding depreciation and amortization and impairments, as they are recurring non-cash variables which can vary substantially from company to company depending on accounting policies and the accounting value of the assets. EBITDA is an approximation to pre-tax operating cash flow and reflects cash generation before working capital variation. EBITDA is widely used by investors when evaluating businesses (multiples valuation), as well as by rating agencies and creditors to evaluate the level of debt, comparing EBITDA with net debt.

EBITDA is calculated in the following manner:

EBITDA = Net income for the period + Income tax charges +/- Equity in Earnings (losses) of non-consolidated companies +/- Financial results + Depreciation and amortization +/- Impairment charges/(reversals).

EBITDA is a non-IFRS alternative performance measure.

(all amounts in thousands of U.S. dollars)Three-month period
ended September 30,
Nine-month period
ended September 30,
2024 2023 2024 2023
Income for the period459,191 546,805 1,557,642 2,812,052
Income tax charge133,968 278,200 356,971 851,804
Equity in earnings (losses) of non-consolidated companies(7,605) 110,382 26,735 (38,545)
Financial Results(48,455) (67,486) (80,876) (127,866)
Depreciation and amortization151,122 136,129 465,073 392,163
EBITDA688,221 1,004,030 2,325,545 3,889,608

Free Cash Flow

Free cash flow is a measure of financial performance, calculated as operating cash flow less capital expenditures. FCF represents the cash that a company is able to generate after spending the money required to maintain or expand its asset base.

Free cash flow is calculated in the following manner:

Free cash flow = Net cash (used in) provided by operating activities - Capital expenditures.

Free cash flow is a non-IFRS alternative performance measure.

(all amounts in thousands of U.S. dollars)Three-month period
ended September 30,
Nine-month period
ended September 30,
2024 2023 2024 2023
Net cash provided by operating activities551,812 1,296,934 2,373,990 3,559,338
Capital expenditures(178,671) (170,376) (512,086) (452,625)
Free cash flow373,141 1,126,558 1,861,904 3,106,713

Net Cash / (Debt)

This is the net balance of cash and cash equivalents, other current investments and fixed income investments held to maturity less total borrowings. It provides a summary of the financial solvency and liquidity of the company. Net cash / (debt) is widely used by investors and rating agencies and creditors to assess the company's leverage, financial strength, flexibility and risks.

Net cash/ debt is calculated in the following manner:

Net cash = Cash and cash equivalents + Other investments (Current and Non-Current)+/- Derivatives hedging borrowings and investments - Borrowings (Current and Non-Current).

Net cash/debt is a non-IFRS alternative performance measure.

(all amounts in thousands of U.S. dollars)At September 30,
2024 2023
Cash and cash equivalents715,028 864,043
Other current investments2,798,807 2,496,747
Non-current investments1,013,474 560,489
Derivatives hedging borrowings and investments- 766
Current borrowings(485,996) (597,493)
Non-current borrowings(14,405) (25,248)
Net cash / (debt)4,026,908 3,299,304

Operating working capital days

Operating working capital is the difference between the main operating components of current assets and current liabilities. Operating working capital is a measure of a company's operational efficiency, and short-term financial health.

Operating working capital days is calculated in the following manner:

Operating working capital days = [(Inventories + Trade receivables - Trade payables - Customer advances) / Annualized quarterly sales ] x 365.

Operating working capital days is a non-IFRS alternative performance measure.

(all amounts in thousands of U.S. dollars)At September 30,
2024 2023
Inventories3,762,705 3,884,882
Trade receivables2,079,600 2,169,293
Customer advances(324,382) (160,533)
Trade payables(962,358) (999,209)
Operating working capital4,555,565 4,894,433
Annualized quarterly sales11,661,948 12,951,344
Operating working capital days143 138


Giovanni Sardagna
Tenaris
1-888-300-5432
www.tenaris.com


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.